Future Oncology

Article	Citations
A Concise Prognostic Score System for Diffuse Large B-Cell Lymphoma: A Retrospective Study with Long-Term Follow-Up	117
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes	85
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	77
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	62
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis	49
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	49
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	44
Is Obesity a Risk Factor in Cancer Patients with COVID-19?	44
Development and Validation of An Immune Gene Set-Based Prognostic Signature in Cutaneous Melanoma	43
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	43
Can Pretreatment Blood Biomarkers Predict Pathological Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer?	41
Sex bias phenomenon in oral cancer: an insight	41
Predicting Amplification of MYCN using CpG Methylation Biomarkers in Neuroblastoma	40
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	39
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	39
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	39
Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice	38
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)	38
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	38
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study	36
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	36
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	36
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe	36
Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges	35
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	35

A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer	34
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	33
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	31
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	30
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon	30
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	29
DUART: Durvalumab After Radiotherapy in Patients with Unresectable, Stage III NSCLC who are Ineligible for Chemotherapy	28
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites	28
Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer	27
Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database	27
Real-World Use and Acceptance of Biosimilar Monoclonal Antibodies of Rituximab in Oncology Practice in the USA	27
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)	26
Serum Exosomal miR-377-3p and miR-381-3p as Diagnostic Biomarkers in Colorectal Cancer	26
Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?	26
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design	26
Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database	25
Association Between Event-Free Survival and Overall Survival in Early-Stage Triple-Negative Breast Cancer	25
Treatment Patterns and Overall Survival in HER2+ Metastatic Breast Cancer at US Community Oncology Practices	25
Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis	24
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer	24
A Multicenter Randomized, Controlled Clinical Trial of Adjuvant Sintilimab for Esophageal Squamous Cell Carcinoma	24
The treatment of advanced pulmonary sarcomatoid carcinoma	23
Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study	22
Overcoming Immunosuppression and Pro-Tumor Inflammation in Lung Cancer with Combined IL-1β and PD-1 Inhibition	22
Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study	22
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer	22
The ‘Hit-and-Run’ Strategy and Viral Carcinogenesis	22
Highlights of the San Antonio Breast Cancer Symposium 2020: Part 2	22
Pembrolizumab: First Adjuvant Immunotherapy in Renal Cell Carcinoma?	22
Real-World Cost–Effectiveness of Primary Prophylaxis with G-CSF Biosimilars in Patients at Intermediate/High Risk of Febrile Neutropenia	22
Outcomes of Level of Ligation of Inferior Mesenteric Artery in Colorectal Cancer: a Systematic Review and Meta-Analysis	21
LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma	21
Preferences for First-Line Treatment of Advanced Urothelial Carcinoma among US Practicing Oncologists and Patients	21
Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer	21
Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada	21
Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review	21
Patient Engagement in Cancer Research from the Patient’s Perspective	21
Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients	21
Correction	20
Augmented Intelligence to Predict 30-day Mortality in Patients with Cancer	20
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer	20
Oncolytic Virotherapy as Promising Immunotherapy Against Cancer: Mechanisms of Resistance to Oncolytic Viruses	20
Intraperitoneal Infusion of Recombinant Human Endostatin Improves Prognosis in Gastric Cancer Ascites	20
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review	20
The Importance of the Glucose-To-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Treated with Sorafenib	20
Association of human papillomavirus with breast cancer: a new perspective on an old debate	20
Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice	19
G-CSF and G-CSF-Related Vasculitis: A Systematic Review of the Literature and Intriguing Future Research Perspectives	19
Upfront Cytoreductive Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer in Indian Patients	19
Multimodal Analysis of ctDNA Methylation and Fragmentomic Profiles Enhances Detection of Nonmetastatic Colorectal Cancer	19

Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-	19
Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA	19
Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment	19
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC tri	19
Effect of preoperative peripheral blood platelet volume index on prognosis in patients with invasive breast cancer	18
As a Potential Predictor of Pan-Cancer, UBE2S is Related to Tumor-Associated Macrophage Infiltration	18
Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers	18
Application and Prospect of Single-Cell Sequencing in Cancer Metastasis	18
Does Failed Mapping Predict Sentinel Lymph Node Metastasis in cN0 Breast Cancer?	18
An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection	18
Next-Generation Sequencing of Cancer Genomes: Lessons Learned	17
Real-world Evidence of Multiple Myeloma Treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland	17
The Benefit of Immunotherapy in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis	17
Small Cell Carcinoma as an Independent Prognostic Factor for Cervical Cancer Patients: A Population-Based Analysis	17
Lorlatinib as a treatment for ALK-positive lung cancer	17
Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping	17
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients	16
Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma	16
Clinical Effectiveness of Transcatheter Arterial Chemoembolization Sequential Microwave Ablation For Lack of Blood Supply in Hepatocellular Carcinoma	16
Construction of methylation-associated nomogram for predicting the recurrence-free survival risk of stage I–III lung adenocarcinoma	16
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission	16
RAB1A Regulates Glioma Cellular Proliferation and Invasion Via the mTOR Signaling Pathway and Epithelial–Mesenchymal Transition	15
The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer	15
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer: A Plain Language Summary Of The DESTINY-Gastric01 Study	15
An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: ‘R-ISV-FOLactis’ trial	15
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study	15
Expanded Access to Anticancer Treatments from Conversion to Biosimilar Pegfilgrastim-cbqv in US Breast Cancer Patients	15
Optimal Examined Lymph Node Count in Node-Negative Colon Cancer Should be Determined	15
Relationship Between Nurses’ Perceptions and Financial Toxicity Management in the Public Health Insurance System	15
Metabolic syndrome and symptom burden in allogeneic hematopoietic stem cell transplantation survivors	15
Nomogram to predict overall survival in patients with primary bladder neuroendocrine carcinoma: a population-based study	15
Exploring the Connection Between Microsatellite Instability and Inflammatory Indicators in Cancers	15
Analysis of the Expression Patterns and Clinical Relevance of m 6 A Regulators in 33 Cancer Types	15
AMELIORATE: Early Intensification in FLT3 -Mutated Acute Myeloid Leukemia Based on Peripheral Blast Clearance – MYNERVA-GIMEMA AML1919 Trial	15
Cancer staff in an NHS cancer center: infections, vaccination, stress and well-being support during the COVID-19 pandemic	15
Corrigendum	14
Pediatric oncohematological exercise program in hospital: clinical trial study protocol	14
Predictors of Poor Precautionary Practices Towards COVID-19 Among Cancer Patients	14
Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a	14
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies	14
The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index	14
Guideline Conformity to the Stupp Regimen in Patients with Newly Diagnosed Glioblastoma Multiforme in China	13
A Critical Appraisal on Cancer Prognosis and Artificial Intelligence	13
Outdoor air pollution and oral cancer: critical viewpoints and future prospects	13
Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey	13
Plain language summary and patient perspective of the revised STARS study: long-term results of a study that compared the effectiveness of radiotherapy to surgery in people with non-small-cell lung ca	13
Co-expression of CD44v6 and MMP2 predicts lung metastasis and unfavorable prognosis in osteosarcoma	13
CSF1 Receptor Inhibition of Tenosynovial Giant Cell Tumor Using Novel Disease-Specific MRI Measures of Tumor Burden	13
Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey	13
Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma	12
Immune Checkpoint Inhibitors Plus Anlotinib Versus Anlotinib Alone as Third-Line Treatment in Advanced Non-Small-Cell Lung Cancer: A Retrospective Study	12
Hypersensitivity Reactions to Asparaginase Therapy in Acute Lymphoblastic Leukemia: Immunology and Clinical Consequences	12
Gastric cancer in pregnancy: a review	12
Revolutionizing colorectal cancer treatment: unleashing the potential of miRNAs in targeting cancer stem cells	12
The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer	12
A Risk-Group Classification Model in Patients with Bladder Cancer Under Neoadjuvant Cisplatin-Based Combination Chemotherapy	12
Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia	12
Extension of lymph node dissection in the surgical treatment of esophageal and gastroesophageal junction cancer: seven questions and answers	12
Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database	12
Prognostic Significance of the Systemic Inflammation Response Index in Gastrointestinal Malignancy Patients: A pooled Analysis of 10,091 Participants	12
Deep learning-based multiomics integration model for predicting axillary lymph node metastasis in breast cancer	12
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel	11
Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation	11
Methylation site APC 112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence	11
A Randomized Controlled Trial to Evaluate Omentum-Preserving Gastrectomy for Patients with T1–T3 Gastric Cancer	11
Long-term outcomes of stage IIB–IV melanoma patients: nationwide data from Norway	11
Systematic Literature Review of Current Treatments for Stage I–III Merkel Cell Carcinoma	11
Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence	11
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?	11
Temporal Trends of Adverse Events and Costs of Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal Cell Carcinoma	11
Safety and efficacy of left colic artery preservation in laparoscopic anterior resection for lower rectal cancer	11
Pralsetinib in Patients with RET Fusion–Positive Non-Small-Cell Lung Cancer: A Plain Language Summary of the ARROW Study	10
CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma	10
Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer	10
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary	10
Perspective on the Risk of Suicide Associated with Oral Cancer Diagnosis	10
Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors	10
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion	10
Detection and Verification of Coexisting Diagnostic Markers in Plasma and Serum of Patients with Non-Small-Cell Lung Cancer	10
Palliative and End-Of-Life Symptoms Management for Children with Diffuse Intrinsic Pontine Glioma	10

Evaluation of the prognostic effectiveness of liver metastasis volume by volumetric measurement in colorectal cancer	10
Benefit-Risk Trade-Offs in Treatment Choice in Advanced HER2 Negative Breast Cancer: Patient and Oncologist Perspectives	10
Engineered exoASO-STAT6: a potent monotherapy for oral squamous cell carcinoma	10
Long-term Results from a Clinical Study of Xevinapant Plus Chemoradiotherapy in People With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Plain Language Summary	10
The Correlation Between Skeletal Muscle Index and Anxiety in Patients with Lung Cancer on the First Day of Chemotherapy	10
Desmoid Fibromatosis: is the Current Picture Changing?	10
Research progress on the role of lipoxygenase and its inhibitors in prostate cancer	10
Unsupervised Learning of Cross-Modal Mappings in Multi-Omics data for Survival Stratification of Gastric Cancer	10
A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma	9
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resist	9
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary	9
A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006	9
Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis	9
Methylated ZNF582 as a triage marker for occult cervical cancer and advanced cervical intraepithelial neoplasia	9
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for hepatocellular carcinoma: a meta-analysis	9
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?	9
Tebentafusp for the Treatment of Metastatic Uveal Melanoma	9
Reliability, Validity and Important Difference Estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)	9
NeoSCORE II: Three Vs Four Cycles of Neoadjuvant Sintilimab + Chemotherapy for Squamous Non-Small-Cell Lung Cancer	9
DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer	9
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma	9
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer	9
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies	9
Improved Outcomes and Staging in Non-Small-Cell Lung Cancer Guided by A Molecular Assay	9
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma	9
Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA	9
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study	9
Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma	9
Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia	9
Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact ® survey 2021	9
Plain language summary and patient perspective of the 2020 lung cancer screening recommendations by the US Preventive Services Task Force	9
KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer	9
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis	9
The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma	9
Perceptions of the COVID-19 vaccine Among Patients With Cancer: A Single-Institution Survey	9
Inhibition of DNA Damage Response Pathway Using Combination of DDR Pathway Inhibitors and Radiation in Treatment of Acute Lymphoblastic Leukemia Cells	9
Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study	9
Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma	8
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review	8
Real-world Management Patterns in EGFR -mutant Advanced Non-Small-Cell Lung Cancer before First-Line Adoption of Osimertinib: The REFLECT Study in Greece	8
The Role of Surgery in Metastatic Cancer: The Case For a Pragmatic Tumor-Agnostic Randomized Trial	8
Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer	8
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy	8
Downregulation of ACE2 is associated with advanced pathological features and poor prognosis in clear cell renal cell carcinoma	8
Keeping the Balance, the True Major Goal in Advanced Sarcoma	8
Extended distal pancreatectomy in pancreatic cancer: is it justified? A systematic review of literature	8
Association of Polymorphisms in PIN1 with Progression And Susceptibility in Gastric Cancer	8
Characterization of the immune environment in pregnancy-associated breast cancer	8
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA	8
Prognostic Value of GPC5 Polymorphism rs2352028 and Clinical Characteristics in Chinese Lung Cancer Patients	8
The Management of a Breast Unit During the COVID-19 Emergency: A Local Experience	8
Retrospective study of total neoadjuvant therapy for locally advanced rectal cancer	8
Economic Burden of Central Nervous System Metastases in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer	8
Development and validation of a Cancer Patient Suicidal Ideation Scale	8
Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations	8
Value of Biomarkers in Epithelial–Mesenchymal Transition Models Of Liver Cancer Under Different Interventions: A Meta-Analysis	8
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma	8
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases	8
Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis	8
Real-World Outcomes of Pomalidomide Therapy after Lenalidomide Induction in Relapsed/Refractory Multiple Myeloma	8
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial	7
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?	7
PALVEN: Phase Ib Trial of Palbociclib, Letrozole and Venetoclax in Estrogen Receptor- and BCL2-Positive Advanced Breast Cancer	7
Diagnostic journey and life impact of cholangiocarcinoma: results from surveys of patient and caregiver experiences	7
Effect of Lateral Lymph Nodes Without Malignant Characteristics on the Prognosis of Patients with Rectal Cancer	7
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer	7
Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case–control study	7
Plain Language Summary of the Final Results from the GioTag Study	7
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study	7
The impact of myelosuppression on quality of life of patients treated with chemotherapy	7
First Advanced Course on Biomarkers in Molecular and Immuno-Oncology in the Middle East	7
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer	7
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data	7
Correction	7
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary	7
Prognostic Factors Affecting Infantile Medulloblastoma Outcomes in the Molecular Era: A 12-year Single-Center Experience from Egypt	7
Corrigendum	7
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer	7
Highlights of the San Antonio Breast Cancer Symposium 2020: Part 1	7
Prognostication for Surgically Treated Papillary Renal Cell Carcinoma: Which Model is the Optimal Choice?	7
The Effects of Managing Cancer and Living Meaningfully (CALM) on Psychological Distress in Esophageal Cancer Patients	7
Corrigendum	7
Frontline anti-PD-1/PD-L1 Versus Bevacizumab in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis	7
Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population	7
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023)	7
Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China	7
Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration Schedule	7
siRNA-Based Approaches for Castration-Resistant Prostate Cancer Therapy Targeting the Androgen Receptor Signaling Pathway	7
ADJUBIL: Phase II Study of Adjuvant Immunotherapy with STRIDE Regimen With/Without Capecitabine in Biliary Tract Cancers	7
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma	7
Eribulin in Brain Metastases of Breast Cancer: Outcomes of the EBRAIM Prospective Observational Trial	7
The Power of Hope: Views of Ovarian Cancer Patients on How Maintenance Therapy Affects Their Lives (VOCAL)	7
Exploring Exosome Data to Identify Prognostic Gene Signatures for Lung Adenocarcinoma	7
KRAS mutational analysis: a new supplementary diagnostic tool for extrahepatic biliary stenosis	7
Stratification of Axillary Lymph Node Metastasis Risk with Breast MRI in Breast Cancer	7